RhumbLine Advisers’s Oramed Pharmaceuticals ORMP Stock Holding History

RhumbLine Advisers’s Portfolio ORMP Stock Details ORMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$147K	Buy	+30,621	New	+$122K	﹤0.01%	3401
2024 Q3	–	Sell	-1,830	Closed	-$4.7K	–	4294
2024 Q2	$4.7K	Hold	1,830	–	–	﹤0.01%	4095
2024 Q1	$5.34K	Hold	1,830	–	–	﹤0.01%	3974
2023 Q4	$4.23K	Hold	1,830	–	–	﹤0.01%	4011
2023 Q3	$4.78K	Hold	1,830	–	–	﹤0.01%	3988
2023 Q2	$6.55K	Buy	+1,830	New	+$5.87K	﹤0.01%	4037
2022 Q2	–	Sell	-34,046	Closed	-$294K	–	3197
2022 Q1	$294K	Buy	34,046 +9,611	+39%	+$98.5K	﹤0.01%	2649
2021 Q4	$349K	Buy	24,435 +2,212	+10%	+$46.2K	﹤0.01%	2659
2021 Q3	$488K	Buy	22,223 +8,241	+59%	+$140K	﹤0.01%	2552
2021 Q2	$187K	Buy	+13,982	New	+$160K	﹤0.01%	2928

Other funds holding ORMP

Mercer Global Advisors Denver, Colorado $80.9B AUM 26.08% 1-Year Est. Return

Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return

GIA

Gem Investment Advisors Teaneck, New Jersey $163M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RhumbLine Advisers's ORMP Position: Q2 2026 in Review

RhumbLine Advisers opened a new position in Oramed Pharmaceuticals (ORMP) in Q2 2026: 30,621 shares worth $147K. The stake represents ﹤0.01% of the portfolio and ranks #3401 among its holdings. This is a return to the name: RhumbLine Advisers previously reported a position in ORMP as recently as Q2 2024.

RhumbLine Advisers first reported a position in ORMP in Q2 2021 and has held it in 10 quarters since. The position peaked at $488K in Q3 2021. 84 funds tracked by Wall St. Rank hold ORMP as of Q2 2026.

RhumbLine Advisers held 30,621 shares of Oramed Pharmaceuticals worth $147K as of Q2 2026.
Oramed Pharmaceuticals was a new RhumbLine Advisers position in Q2 2026.
Oramed Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #3401 holding.
RhumbLine Advisers first reported a position in Oramed Pharmaceuticals in Q2 2021 and has held it in 10 quarters since.
RhumbLine Advisers's Oramed Pharmaceuticals position peaked at $488K in Q3 2021.
84 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.